Notable Labs Ltd
NASDAQ:NTBL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Dynagas LNG Partners LP
NYSE:DLNG
|
MC |
|
L
|
Lloyds Banking Group PLC
NYSE:LYG
|
UK |
Notable Labs Ltd
EPS (Diluted)
Notable Labs Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Notable Labs Ltd
NASDAQ:NTBL
|
EPS (Diluted)
-$1
|
CAGR 3-Years
50%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
EPS (Diluted)
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
EPS (Diluted)
$0
|
CAGR 3-Years
29%
|
CAGR 5-Years
4%
|
CAGR 10-Years
35%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
EPS (Diluted)
-$3
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
EPS (Diluted)
$0
|
CAGR 3-Years
-12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
EPS (Diluted)
-$2
|
CAGR 3-Years
29%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
|
Notable Labs Ltd
Glance View
Notable Labs Ltd is a IL-based company operating in Biotechnology industry. Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The firm's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
See Also
What is Notable Labs Ltd's EPS (Diluted)?
EPS (Diluted)
-1.8
USD
Based on the financial report for Jun 30, 2024, Notable Labs Ltd's EPS (Diluted) amounts to -1.8 USD.
What is Notable Labs Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
37%
Over the last year, the EPS (Diluted) growth was 75%. The average annual EPS (Diluted) growth rates for Notable Labs Ltd have been 50% over the past three years , 37% over the past five years .
